Valued at $199
Included with a Subscription to Equio®
Want the full report?
Already a subscriber? Login
From Prescription to Recommendation: How Cannabis Could Disrupt the Pharmaceutical Industry
In our latest study, From Prescription to Recommendation: How Cannabis Could Disrupt the Pharmaceutical Industry, our data analysts have found that if medical cannabis were legalized nationally, pharmaceutical expenditures on the top nine conditions commonly treated by medical cannabis could fall an estimated $18.5 billion between 2016 and 2019.
The study looks at the impact to pharmaceutical sales on the nine ailments most commonly treated with cannabis which are:
- Chronic Pain
- Post-Traumatic Stress Disorder (PTSD)
- Sleep Disorders
- Anxiety
- Nerve Pain
- Chemotherapy Induced Nausea and Vomiting (CINV)
- Tourette Syndrome
- Glaucoma
- Seizures/Epilepsy
Find out what’s next for medical cannabis and the pharmaceutical industry in your FREE copy of our study today!
*Published in May 2017
